1.20
+0(+0.00%)
Currency In USD
| Previous Close | 1.2 |
| Open | 1.17 |
| Day High | 1.21 |
| Day Low | 1.16 |
| 52-Week High | 2.74 |
| 52-Week Low | 0.87 |
| Volume | 239,699 |
| Average Volume | 608,182 |
| Market Cap | 44.44M |
| PE | -1.62 |
| EPS | -0.74 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 1.61 |
| Change | 0 |
If you invested $1000 in MAIA Biotechnology, Inc. (MAIA) since IPO date, it would be worth $269.06 as of December 07, 2025 at a share price of $1.2. Whereas If you bought $1000 worth of MAIA Biotechnology, Inc. (MAIA) shares 2 years ago, it would be worth $1,316.01 as of December 07, 2025 at a share price of $1.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
GlobeNewswire Inc.
Dec 01, 2025 2:17 PM GMT
CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO an
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
GlobeNewswire Inc.
Nov 21, 2025 2:01 PM GMT
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: M
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
GlobeNewswire Inc.
Nov 20, 2025 1:47 PM GMT
Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”,